Member Info for TrickyEFC

159million someone has just bought 👀

£20k buy

Nice action. Have finger up bum n exman packed it in now??

Is skid still posting? Surely not?

One day old posters pumping this.

...

At 0.30p fo that size if it is a sell it's good sign also.

Give us 0.5 by second week of Jan.

Let's get to fair value for starters.

If funding news for svns 001 drops it's going to be closer to 3pps

Move the market cap from £20mill to £200mil.

Just need the board to deliver what they have alluded to and it sailing there.

17:06:28 0.30 10,250,000 Unknown* 30.75k

Going of the previous trades looks like a buy.

Some decent buying going on again.

Into the 3s we go

Well if 50 trades can shift it 10%

Imagine what so long overdue positive news would do

The darts is on so why not 😉

At 58 too. The days high

Few more of those and we may keep the rise

To break the years high and onto £2

Should of bene over 0.5p months ago

When it want too

29-Dec-25 15:56:51 0.2778 8,736,911 Buy* 24.27k

Hope everyone had good Xmas.

Dv looks like ya right.

29-Dec-25 13:55:13 0.2804 3,000,000 Buy* 8,412 O

29-Dec-25 13:54:15 0.2654 3,000,000 Sell* 7,962

one out to let one in?

With Solvonis having funding from NIH and the recent America grant funding.

Look at the $31 million in R&D costs that mind medicine have had to cover.

Upside here is truly mindblowing

MindMed’s fiscal 2025 third-quarter update, released on Nov. 6, reflected a company firmly in an investment and development phase rather than one focused on near-term results. The pre-revenue biotech posted a loss of $0.78 per share, wider than last year’s $0.27 loss and below Wall Street’s $0.52 estimate. The miss was not about stalling science, but it was about spending with intent.

Research and development costs surged from $17.2 million in Q3 2024 to $31 million, driven largely by an $11.7 million jump in MM120 program expenses, alongside higher internal staffing costs as the company scaled its R&D engine. General and administrative expenses followed suit, nearly doubling annually to $14.7 million, reflecting heavier investment in people, commercial readiness, and corporate infrastructure. In short, MindMed spent more because it chose to move faster.

Right have a read of this.

Mimd medicine.Wall street thinks this stock can do over 300% in 2026. Given that it's currently values at $1.4billion.

Svns current valuation of £17million.

https://www.barchart.com/story/news/36788739/wall-street-thinks-this-1-psychedelic-stock-can-gain-335-in-2026

Some decent action today still look like buyers are hungry for this